When doctors perform a bronchoscopy to look for lung cancer, they need to be as accurate as possible. A new approach called rapid on-site evaluation (ROSE) allows them to check tissue samples immediately during the procedure rather than waiting for lab results later.
This analysis looked at 1,841 cases of peripheral pulmonary lesions. The data showed that ROSE had a high sensitivity of 88.1% and a specificity of 91.7% for detecting lung cancer. For patients who also had a CT scan, the accuracy was even higher, with sensitivity reaching 94.2% and specificity at 96.9%.
While these results show that ROSE is a reliable tool for doctors to use during bronchoscopy, it is important to remember that this data shows how well the test performs rather than proving a direct cause of better outcomes. It provides clinicians with a more reliable way to confirm cancer in real-time.
Common questions
What is rapid on-site evaluation (ROSE)?
Rapid on-site evaluation, or ROSE, is a method where medical professionals check tissue samples immediately during a bronchoscopy procedure. Instead of waiting for laboratory results later, this allows doctors to confirm the presence of lung cancer more quickly while they are still performing the procedure.
How accurate is this test for lung cancer?
The study found that ROSE has a high sensitivity of 88.1% and a specificity of 91.7% for detecting lung cancer in patients with peripheral pulmonary lesions. For those who also had a CT scan, the accuracy was even higher, with sensitivity at 94.2% and specificity at 96.9%.
Is this test used during bronchoscopy?
Yes, this method is specifically used during endobronchial ultrasound-guided bronchoscopy (EBUS-TBNA). It helps doctors confirm cancer detection in real-time. When a guide sheath was used with the equipment, the sensitivity for the test was 88.5%.
